Alembic Limited manufactures and markets fermentation and chemistry based active pharmaceuticals ingredients (API). More Details
Flawless balance sheet with outstanding track record.
Share Price & News
How has Alembic's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 506235 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 506235's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 506235 exceeded the Indian Pharmaceuticals industry which returned 47.9% over the past year.
Return vs Market: 506235 exceeded the Indian Market which returned 41% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Alembic's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Alembic undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 506235 (₹100.6) is trading above our estimate of fair value (₹8.87)
Significantly Below Fair Value: 506235 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 506235 is good value based on its PE Ratio (6.7x) compared to the IN Pharmaceuticals industry average (19.7x).
PE vs Market: 506235 is good value based on its PE Ratio (6.7x) compared to the Indian market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 506235's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 506235 is good value based on its PB Ratio (1.4x) compared to the IN Pharmaceuticals industry average (2.3x).
How is Alembic forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Alembic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Alembic is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Alembic competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Alembic performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 506235 has high quality earnings.
Growing Profit Margin: 506235's current net profit margins are higher than last year .
Past Earnings Growth Analysis
Earnings Trend: 506235's earnings have grown significantly by 20.9% per year over the past 5 years.
Accelerating Growth: 506235's earnings growth over the past year (52.9%) exceeds its 5-year average (20.9% per year).
Earnings vs Industry: 506235 earnings growth over the past year (52.9%) exceeded the Pharmaceuticals industry 39.9%.
Return on Equity
High ROE: 506235's Return on Equity (20.2%) is considered high.
How is Alembic's financial position?
Financial Position Analysis
Short Term Liabilities: 506235's short term assets (₹1.5B) exceed its short term liabilities (₹545.7M).
Long Term Liabilities: 506235's short term assets (₹1.5B) exceed its long term liabilities (₹230.5M).
Debt to Equity History and Analysis
Debt Level: 506235 is debt free.
Reducing Debt: 506235 had no debt 5 years ago.
Debt Coverage: 506235 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 506235 has no debt, therefore coverage of interest payments is not a concern.
What is Alembic current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 506235's dividend (0.6%) is higher than the bottom 25% of dividend payers in the Indian market (0.42%).
High Dividend: 506235's dividend (0.6%) is low compared to the top 25% of dividend payers in the Indian market (1.76%).
Stability and Growth of Payments
Stable Dividend: 506235's dividend payments have been volatile in the past 10 years.
Growing Dividend: 506235's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (4%), 506235's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Malika Amin (65 yo)
Mrs. Malika C. Amin has been the Chief Executive Officer and Managing Director at Alembic Limited since February 1, 2017. Mrs. Amin served as the Managing Director of Aavaran Ltd. Mrs. Amin serves as the C...
CEO Compensation Analysis
Compensation vs Market: Malika's total compensation ($USD196.16K) is below average for companies of similar size in the Indian market ($USD349.29K).
Compensation vs Earnings: Malika's compensation has been consistent with company performance over the past year.
|MD, CEO & Executive Director||no data||₹14.37m||2.99% |
|Chief Financial Officer||6.58yrs||₹6.81m||0% |
|Compliance Officer & Company Secretary||5.75yrs||₹1.42m||no data|
|Chief Business Development Officer||no data||₹4.30m||0.75% |
|President of API Business & Generic Alliances||15.83yrs||no data||no data|
Experienced Management: 506235's management team is seasoned and experienced (6.6 years average tenure).
|MD, CEO & Executive Director||no data||₹14.37m||2.99% |
|Chairman||no data||₹130.00k||3.24% |
|Non-Executive Director||7.92yrs||₹190.00k||no data|
|Independent Director||8.58yrs||₹340.00k||no data|
|Non-Executive Non-Independent Director||6.33yrs||₹150.00k||no data|
|Non Executive Independent Director||6.08yrs||₹255.00k||no data|
|Independent Director||1.83yrs||₹230.00k||0.0070% |
|Independent Director||1.58yrs||₹80.00k||no data|
Experienced Board: 506235's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alembic Limited's company bio, employee growth, exchange listings and data sources
- Name: Alembic Limited
- Ticker: 506235
- Exchange: BSE
- Founded: 1907
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹25.832b
- Shares outstanding: 256.78m
- Website: https://www.alembiclimited.com
Number of Employees
- Alembic Limited
- Alembic Road
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|506235||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||May 1996|
|ALEMBICLTD||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||May 1996|
Alembic Limited manufactures and markets fermentation and chemistry based active pharmaceuticals ingredients (API). The company operates through API and Real Estate segments. It is also involved in the con...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/06 12:15|
|End of Day Share Price||2021/03/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.